Tirzepatide mechanism of action: how one peptide engages two incretin receptors.

The short version

The tirzepatide mechanism of action is built on a concept called dual incretin agonism. 'Incretin' refers to gut hormones released after eating that stimulate the pancreas to release insulin in a glucose-dependent way. The body naturally makes two: GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). Earlier drugs in this class targeted only GLP-1. Tirzepatide was engineered from the GIP peptide backbone with modifications that let it also bind and activate the GLP-1 receptor. The result: both receptors are activated by a single molecule. In clinical trials, this dual action consistently produced larger reductions in blood sugar and body weight than GLP-1-only drugs. The why — the receptor-level signalling logic — is what this page documents.

The GIP backbone and the fatty-diacid modification

Tirzepatide is a synthetic linear peptide, 39 amino acids long, built on the sequence of native GIP (glucose-dependent insulinotropic polypeptide, an incretin hormone secreted by K-cells in the small intestinal wall after eating). The native GIP sequence was modified to retain GIP receptor activity while gaining the ability to bind and activate the GLP-1 receptor ^[1].

A C20 fatty diacid (eicosanedioic acid) arm is attached via a glutamic acid linker and two (2-(2-aminoethoxy)ethoxy)acetic acid linker units to the lysine side chain at position 20. This fatty-diacid arm confers high albumin affinity: the peptide binds reversibly to circulating albumin, which dramatically slows its clearance. The result is an elimination half-life of approximately 5 days in humans, enabling once-weekly subcutaneous administration ^[1]. This is the same fatty-acid-conjugation engineering principle used in other long-acting incretin-based therapies.

Molecular identifiers: CAS 2023788-19-2. Molecular formula C225H348N48O68. Molecular weight 4813.53 Da. ATC code A10BX16.

Imbalanced dual agonism and biased GLP-1R signalling

Receptor-occupancy and signalling assays (Willard et al., 2020) characterised tirzepatide as an imbalanced dual agonist ^[2]. 'Imbalanced' means it does not engage both receptors with equal potency: tirzepatide engages the GIP receptor (GIPR) to a greater degree than the GLP-1 receptor (GLP-1R).

At the GLP-1R, tirzepatide also shows biased agonism — it preferentially activates the cAMP (cyclic adenosine monophosphate) signalling pathway over beta-arrestin recruitment. cAMP is the primary intracellular messenger that drives insulin secretion from beta-cells. Beta-arrestin, by contrast, promotes receptor internalisation (removal of the receptor from the cell surface), which limits the duration and strength of the insulin signal. By favouring cAMP over beta-arrestin, tirzepatide may sustain the insulinotropic signal longer than a non-biased agonist. In primary islet experiments, beta-arrestin1 limited the insulin response to native GLP-1 but not to GIP or tirzepatide ^[2].

A 2024 pharmacological study across wildtype and variant GIP receptors (E354 and Q354) confirmed tirzepatide favours cAMP signalling at both variants while having weaker effects on other downstream pathways (IP1, AKT, ERK1/2, CREB), reinforcing the biased Gas/cAMP characterisation ^[10].

A cryo-EM structural study (Zhao et al., 2022) resolved tirzepatide bound to the GIP receptor and to the GLP-1 receptor at near-atomic resolution, revealing the key receptor-ligand contacts that underlie the dual engagement and distinguishing the binding mode from single agonists ^[8].

Downstream signalling: what both receptors do once engaged

GIP receptor (GIPR) activation: glucose-dependent insulin secretion from pancreatic beta-cells; modulation of insulin resistance in adipose tissue; effects on bone and on the central nervous system suppression of food intake ^[9]. In obese mice lacking the GLP-1 receptor, tirzepatide still improved insulin sensitivity — specifically by enhancing glucose disposal in white adipose tissue via a GIPR-dependent, weight-independent mechanism. A long-acting GIPR agonist (LAGIPRA) reproduced this effect. Both agents reduced circulating branched-chain amino acids and upregulated glucose, lipid, and branched-chain amino acid catabolic genes in brown adipose tissue [10a = TIRZEPATIDE-c32462f2].

GLP-1 receptor (GLP-1R) activation: glucose-dependent insulin secretion; glucagon suppression (glucagon is the hormone that raises blood glucose between meals); slowed gastric emptying (the rate at which the stomach passes its contents into the small intestine, which blunts post-meal glucose spikes); central nervous system appetite suppression ^[9].

Both GIPR and GLP-1R are expressed across liver, muscle, adipose tissue, central nervous system, heart, and kidney — enabling tirzepatide's dual engagement to produce cardiometabolic benefits through multiple partly distinct tissue-level pathways ^[9]. In human islets, blocking the GIP receptor with an antagonist consistently reduced tirzepatide-stimulated insulin secretion, confirming that the GIPR contribution is real and human-relevant ^[11].

By contrast, in mouse islets the same GIP-receptor block had little effect on tirzepatide-stimulated insulin secretion — in mice, GLP-1R drives more of the insulinotropic effect because tirzepatide has reduced potency at the mouse GIPR. This species difference is important for interpreting preclinical data ^[11].

Why dual agonism outperforms GLP-1 agonism alone

The additive and potentially synergistic effects of engaging both incretin receptors are documented in both preclinical and clinical data. In the 2018 discovery study, tirzepatide reduced body weight and food intake in mice significantly more than a selective GLP-1 receptor agonist at comparable doses ^[1]. In SURPASS-2, the head-to-head phase 3 RCT in 1879 adults with type 2 diabetes, tirzepatide at all three doses (5, 10, 15 mg once weekly) was superior to semaglutide 1 mg — a selective GLP-1 receptor agonist — on HbA1c reduction and on body-weight reduction ^[3]. In SURMOUNT-5, the head-to-head obesity RCT in 751 adults, tirzepatide produced a mean weight change of -20.2% versus -13.7% with the comparator over 72 weeks ^[5].

Two mechanisms are proposed for the advantage over GLP-1-only agents: (1) the additive insulinotropic and weight-reducing effects of GIPR activation on top of GLP-1R activation; and (2) the biased, cAMP-favouring GLP-1R signalling that sustains the insulin signal by reducing receptor internalisation ^[2]. A pharmacological review of GIPR/GLP-1R dual agonist therapies contextualises tirzepatide within the broader class and its clinical applications ^[37].

The structural basis — the specific receptor-contact geometry that enables a single 39-amino-acid peptide to productively engage two distinct G-protein-coupled receptors — is documented in the cryo-EM structures ^[8] and the pharmacological characterisation ^[2]. The mechanism of action is the foundation of Tirzepatide research.